Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 22:16:259-272.
doi: 10.2147/IJGM.S385772. eCollection 2023.

Thrombotic Pathogenesis and Laboratory Diagnosis in Cancer Patients, An Update

David Bolaji Akinbo  1   2 , Olutayo Ifedayo Ajayi  3
Affiliations
Review

Thrombotic Pathogenesis and Laboratory Diagnosis in Cancer Patients, An Update

David Bolaji Akinbo et al. Int J Gen Med. .

Abstract

Cancer-associated thrombosis (CAT) is a leading cause of mortality in cancer patients and its incidence varies in different parts of the world. Venous thromboembolism (VTE) is a prominent manifestation of CAT, and significantly impacts morbidity and survival compared to arterial thrombosis in cancer patients. Several risk factors for developing VTE such as chemotherapy and immobilization have also been found co-existing with cancer patients and contributing to the increased risk of VTE in cancer patients than in non-cancer patients. This review highlights recent mechanisms in the pathogenesis of hypercoagulable syndromes associated with cancer, multiple mechanisms implicated in promoting cancer-associated thrombosis and their diagnostic approaches. Cancer cells interact with every part of the hemostatic system; generating their own procoagulant factors, through stimulation of the prothrombotic properties of other blood cell components or the initiation of clotting by cancer therapies which can all directly activate the coagulation cascade and contribute to the VTE experienced in CAT. It is our hope that the multiple interconnections between the hemostatic system and cancer biology and the improved biomarkers reported in this study can be relevant in establishing a predictive model for VTE, optimize early detection of asymptomatic microthrombosis for more personalized prophylactic strategies and incorporate effective therapeutic options and patient management to reduce mortality and morbidity, and improve the quality of life of affected cancer patients.

Keywords: Trousseau’s syndrome; cancer; hemostasis; laboratory diagnosis; thrombosis; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic representation of the direct mechanisms for cancer-associated thrombosis.
Figure 2
Figure 2
Schematic representation of the indirect mechanisms for cancer-associated thrombosis.
See this image and copyright information in PMC

References

    1. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):1–18. doi:10.1038/s41572-022-00336-y - DOI - PubMed
    1. Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancer-related hypercoagulability. Cancers. 2020;12(3):566. doi:10.3390/cancers12030566 - DOI - PMC - PubMed
    1. Stark K, Schubert I, Joshi U, et al. Distinct pathogenesis of pancreatic cancer microvesicle–associated venous thrombosis identifies new antithrombotic targets in vivo. Arterioscler Thromb Vasc Biol. 2018;38:772–786. doi:10.1161/ATVBAHA.117.310262 - DOI - PubMed
    1. Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83. doi:10.1016/j.critrevonc.2017.08.003 - DOI - PubMed
    1. Levi M. Cancer-related coagulopathies. Thromb Res. 2014;133:S70–S75. doi:10.1016/S0049-3848(14)50012-6 - DOI - PubMed